Showing results (31-40 of 140) with videos related to

Sort By:
Pageof 14
JCO Precision Oncology|July 10, 2025
Clinical Significance of TERT Promoter Mutations in NeuroblastomaNatasha Persaud, Gunes Gundem, Brian H Kushner, et al.
Pediatric Blood & Cancer|June 24, 2008
Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomideBrian H Kushner, Michael P Laquaglia, Kim Kramer, et al.
Pediatric Blood & Cancer|March 31, 2026
Low-Dose Intravenous Ketamine for Primary Pain Control During Naxitamab Anti-GD2 Immunotherapy TreatmentRosanna Silber, Benjamin Record, Nicole Fernandez, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2008
Management and outcome of stage 3 neuroblastomaShakeel Modak, Brian H Kushner, Michael P LaQuaglia, et al.
Clinical Nuclear Medicine|August 1, 2017
Assessment of Organ Dosimetry for Planning Repeat Treatments of High-Dose 131I-MIBG Therapy: 123I-MIBG Versus Posttherapy 131I-MIBG ImagingNeeta Pandit-Taskar, Pat Zanzonico, Patrick Hilden, et al.
Pediatric Blood & Cancer|January 24, 2017
Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II studyShakeel Modak, Brian H Kushner, Ellen Basu, et al.
Pediatric Blood & Cancer|August 28, 2009
A focal lesion in the falx cerebri: Harbinger of classic stage 4 neuroblastoma in an infant cured despite residual disease after minimal therapyBrian H Kushner, Kim Kramer, Shakeel Modak, et al.
Pediatric Blood & Cancer|August 27, 2005
Liver involvement in neuroblastoma: the Memorial Sloan-Kettering Experience supports treatment reduction in young patientsBrian H Kushner, Kim Kramer, Michael P LaQuaglia, et al.
Cancer|June 22, 2010
Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastomaBrian H Kushner, Kim Kramer, Shakeel Modak, et al.
Pediatric Blood & Cancer|January 20, 2006
High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapyBrian H Kushner, Irene Y Cheung, Kim Kramer, et al.
Pageof 14